Skip to main content

Table 1 Clinicopathological data and DTC status at BM1 and BM3

From: Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival

Variable

Number of patients (N)

DTC+ at BM1

n/number assessedd (%)

P-value

DTC+ at BM3

n/number assessedd (%)

P-value

Total number

236

49/231 (21.2)

 

43/162 (26.5)

 

Median age, years (range)

51 (25-70)

    

cT status:

  

0.471b

 

0.659b

   cT0-cT3

187

37/183 (20.2)

 

36/132 (27.3)

 

   cT4

49

12/48 (25.0)

 

7/30 (23.3)

 

cN status

  

0.654b

 

0.203b

   cN0

98

19/95 (20.0)

 

15/69 (21.7)

 

   cN1

104

21/103 (20.4)

 

20/74 (27.0)

 

   cN2-4

34

9/33 (27.3)

 

8/19 (42.1)

 

M status

  

0.162b

 

0.109ª

   M1

25

8/25 (32.0)

 

6/13 (46.2)

 

   M0

211

41/206 (19.9)

 

37/149 (24.8)

 

Hormone receptor status

     

Estrogen receptor

  

0.332ª

 

0.816ª

   ER-pos

133

32/131 (24.4)

 

27/101 (26.7)

 

   ER-neg

98

16/95 (16.8)

 

16/58 (27.6)

 

   Unknown

5

    

Progesterone receptor

  

0.072ª

 

0.478ª

   PgR-pos

113

30/110 (27.3)

 

26/88 (29.5)

 

   PgR-neg

118

18/116 (15.5)

 

16/71 (22.5)

 

   Unknown

5

    

Histological grade

  

0.666b

 

0.960ª

   Grade 1

14

4/13 (30.8)

 

3/12 (25.0)

 

   Grade 2

98

21/96 (21.9)

 

20/72 (27.8)

 

   Grade 3

110

22/108 (20.4)

 

18/72 (25.0)

 

   Unknown

14

    

Response

  

1.000ª

 

0.784ª

   Complete response

10

2/10 (20.0)

 

1/6 (16.7)

 

   Partial response

108

22/104 (21.2)

 

19/79 (24.1)

 

   Stable disease

88

18/87 (20.7)

 

15/61 (24.6)

 

   Progression

6

1/6 (16.7)

 

1/2 (50.0)

 

   Unknown

24

    

BM1 status (pretreatment)

    

0.077b

   Positive

49

  

14/37 (37.8)

 

   Negative

182

  

28/121 (23.1)

 

   Unknown

5

    

BM2 status (at surgery)

  

1.000ª

 

0.654ª

   Positive

11

2/11 (18.2)

 

1/7 (14.3)

 

   Negative

58

9/55 (16.4)

 

12/38 (31.6)

 

   Unknown

167

    

BM3 status (at 1 year follow-up)

  

0.077b

  

   Positive

43

14/42 (33.3)

   

   Negative

119

23/116(19.8)

   

   Unknown

74

    

PB1 status (pretreatment)

  

0.033ª

 

0.464ª

   Positive

10

5/10 (50.0)

 

1//2 (50.0)

 

   Negative

209

39/204 (19.1)

 

39/148 (26.4)

 

   Unknown

17

    

PB2 status (at surgery)

  

1.000ª

 

0.298ª

   Positive

1

0/1 (0)

 

1/1 (100.0)

 

   Negative

70

12/67 (17.9)

 

13/46 (28.2)

 

   Unknown

165

    

PB3 status (at 1 year follow-up)

  

0.618ª

 

0.004ª

   Positive

6

2/6 (33.3)

 

5/6 (83.3)

 

   Negative

135

29/131 (22.1)

 

30/133 (22.6)

 

   Unknown

95

    

Relapse c

  

0.642b

 

0.005b

   Yes

98

22/98 (22.4)

 

22/55 (40.0)

 

   No

112

  

21/107 (19.6)

 

Relapse type

     

   Locoregional only

4

0/4 (0)

 

0/2 (0)

 

   Distant metastases (skeletal and/or visceral)

76

18/74 (24.3)

 

15/42 (35.7)

 

   Distant metastases and locoregional

18

4/18 (22.2)

 

7/11 (63.6)

 

Death and cause e

     

   Breast cancer death

106

23/105 (21.9)

 

26/53 (49.1)

 

   Any death

111

25/110 (22.7)

 

27/57 (47.4)

 

   Alive

124

24/120 (20.0)

 

16/105 (15.2)

 
  1. ªP-value computed by Fisher's exact test. bP-value computed by Pearson Chi-square. cRelapse data only for M0. dThe denominator (number assessed) for all fractions in the table represents the number of patients with known DTC status (positive or negative) for the respective parameter. eNo information available from one patient due to non-adherence.cT: clinical tumor status, cN: clinical lymph node status, M status: metastases status, DTC: disseminated tumor cells, BM: bone marrow, PB: peripheral blood.